Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condit...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2021-07, Vol.31 (8), p.2345-2353
Main Authors: Sasso, Ferdinando Carlo, Pafundi, Pia Clara, Caturano, Alfredo, Galiero, Raffaele, Vetrano, Erica, Nevola, Riccardo, Petta, Salvatore, Fracanzani, Anna Ludovica, Coppola, Carmine, Di Marco, Vito, Solano, Antonio, Lombardi, Rosa, Giordano, Mauro, Craxi, Antonio, Perrella, Alessandro, Sardu, Celestino, Marfella, Raffaele, Salvatore, Teresa, Adinolfi, Luigi Elio, Rinaldi, Luca
Format: Article
Language:English
Subjects:
Cardiovascular risk
Direct acting antivirals
Hepatitis C virus
Prediabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c339t-c885bfdb4a04d7c13fe578ebd57c25b42372a73564aebabb5ba55fa5e002de3a3
cites cdi_FETCH-LOGICAL-c339t-c885bfdb4a04d7c13fe578ebd57c25b42372a73564aebabb5ba55fa5e002de3a3
container_end_page 2353
container_issue 8
container_start_page 2345
container_title Nutrition, metabolism, and cardiovascular diseases
container_volume 31
creator Sasso, Ferdinando Carlo
Pafundi, Pia Clara
Caturano, Alfredo
Galiero, Raffaele
Vetrano, Erica
Nevola, Riccardo
Petta, Salvatore
Fracanzani, Anna Ludovica
Coppola, Carmine
Di Marco, Vito
Solano, Antonio
Lombardi, Rosa
Giordano, Mauro
Craxi, Antonio
Perrella, Alessandro
Sardu, Celestino
Marfella, Raffaele
Salvatore, Teresa
Adinolfi, Luigi Elio
Rinaldi, Luca
description Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort. In this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We recorded all CV events occurred during an overall median follow-up of 24 months (IQR 19–34). 770 HCV positive prediabetic patients were enrolled, 398 untreated controls and 372 DAAs treated patients. Overall, the CV events annual incidence was much higher among prediabetic treated patients (1.77 vs. 0.62, p 
doi_str_mv 10.1016/j.numecd.2021.04.016
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2535122531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939475321001861</els_id><sourcerecordid>2535122531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-c885bfdb4a04d7c13fe578ebd57c25b42372a73564aebabb5ba55fa5e002de3a3</originalsourceid><addsrcrecordid>eNp9UDtPwzAYtBBIlMI_YPBYhgQ7tptmQarKo5UqsQCr5ccX6qqJg50U8e9xFWaW73G6O-kOoVtKckro_H6ft0MDxuYFKWhOeJ7AMzShoiIZK4vqHE1IxaqMl4JdoqsY94SwkjA-QXrTdMr02NfYugDpSp9rP7Fqe3d0QR0inj0ul_EO-xYbFazzRxXNcFABwxHaPmLX4vXqAxu_86HH367f4S5AZp3S0EO8Rhd1soGbvz1F789Pb6t1tn192ayW28wwVvWZWSyErq3minBbGspqEOUCtBWlKYTmRUqiSibmXIFWWguthKiVAEIKC0yxKZqNvl3wXwPEXjYuGjgcVAt-iLIQTNAiTZqofKSa4GMMUMsuuEaFH0mJPFUq93KsVJ4qlYTLBCbZwyiDFOPoIMhoHLQGxuqk9e5_g197mIJE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2535122531</pqid></control><display><type>article</type><title>Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes</title><source>ScienceDirect Freedom Collection</source><creator>Sasso, Ferdinando Carlo ; Pafundi, Pia Clara ; Caturano, Alfredo ; Galiero, Raffaele ; Vetrano, Erica ; Nevola, Riccardo ; Petta, Salvatore ; Fracanzani, Anna Ludovica ; Coppola, Carmine ; Di Marco, Vito ; Solano, Antonio ; Lombardi, Rosa ; Giordano, Mauro ; Craxi, Antonio ; Perrella, Alessandro ; Sardu, Celestino ; Marfella, Raffaele ; Salvatore, Teresa ; Adinolfi, Luigi Elio ; Rinaldi, Luca</creator><creatorcontrib>Sasso, Ferdinando Carlo ; Pafundi, Pia Clara ; Caturano, Alfredo ; Galiero, Raffaele ; Vetrano, Erica ; Nevola, Riccardo ; Petta, Salvatore ; Fracanzani, Anna Ludovica ; Coppola, Carmine ; Di Marco, Vito ; Solano, Antonio ; Lombardi, Rosa ; Giordano, Mauro ; Craxi, Antonio ; Perrella, Alessandro ; Sardu, Celestino ; Marfella, Raffaele ; Salvatore, Teresa ; Adinolfi, Luigi Elio ; Rinaldi, Luca</creatorcontrib><description>Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort. In this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We recorded all CV events occurred during an overall median follow-up of 24 months (IQR 19–34). 770 HCV positive prediabetic patients were enrolled, 398 untreated controls and 372 DAAs treated patients. Overall, the CV events annual incidence was much higher among prediabetic treated patients (1.77 vs. 0.62, p &lt; 0.001), and HCV clearance demonstrated to significantly reduce CV events (RR: 0.411, 95%CI 0.148–1.143; p &lt; 0.001), with an estimated NNT for one additional patient to benefit of 52.1. Moreover, an independent association between a lower rate of CV events and HCV clearance after DAAs was observed (OR 4.67; 95%CI 0.44–53.95; p = 0.016). HCV eradication by DAAs allows a significant reduction of MACEs in the prediabetic population, and therefore represents a primary objective, regardless of the severity of liver disease and CV risk factors. •Even in prediabetes HCV infection coexistence exacerbates cardiovascular risk.•HCV clearance demonstrated to significantly reduce CV events.•HCV clearance by DAAs was independently associated with a lower rate of CV events.•The use of DAAs in HCV positive prediabetic patients would be recommended.</description><identifier>ISSN: 0939-4753</identifier><identifier>EISSN: 1590-3729</identifier><identifier>DOI: 10.1016/j.numecd.2021.04.016</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Cardiovascular risk ; Direct acting antivirals ; Hepatitis C virus ; Prediabetes</subject><ispartof>Nutrition, metabolism, and cardiovascular diseases, 2021-07, Vol.31 (8), p.2345-2353</ispartof><rights>2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-c885bfdb4a04d7c13fe578ebd57c25b42372a73564aebabb5ba55fa5e002de3a3</citedby><cites>FETCH-LOGICAL-c339t-c885bfdb4a04d7c13fe578ebd57c25b42372a73564aebabb5ba55fa5e002de3a3</cites><orcidid>0000-0001-7761-7533 ; 0000-0003-3320-3878 ; 0000-0002-9142-7848 ; 0000-0001-6958-927X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Sasso, Ferdinando Carlo</creatorcontrib><creatorcontrib>Pafundi, Pia Clara</creatorcontrib><creatorcontrib>Caturano, Alfredo</creatorcontrib><creatorcontrib>Galiero, Raffaele</creatorcontrib><creatorcontrib>Vetrano, Erica</creatorcontrib><creatorcontrib>Nevola, Riccardo</creatorcontrib><creatorcontrib>Petta, Salvatore</creatorcontrib><creatorcontrib>Fracanzani, Anna Ludovica</creatorcontrib><creatorcontrib>Coppola, Carmine</creatorcontrib><creatorcontrib>Di Marco, Vito</creatorcontrib><creatorcontrib>Solano, Antonio</creatorcontrib><creatorcontrib>Lombardi, Rosa</creatorcontrib><creatorcontrib>Giordano, Mauro</creatorcontrib><creatorcontrib>Craxi, Antonio</creatorcontrib><creatorcontrib>Perrella, Alessandro</creatorcontrib><creatorcontrib>Sardu, Celestino</creatorcontrib><creatorcontrib>Marfella, Raffaele</creatorcontrib><creatorcontrib>Salvatore, Teresa</creatorcontrib><creatorcontrib>Adinolfi, Luigi Elio</creatorcontrib><creatorcontrib>Rinaldi, Luca</creatorcontrib><title>Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes</title><title>Nutrition, metabolism, and cardiovascular diseases</title><description>Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort. In this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We recorded all CV events occurred during an overall median follow-up of 24 months (IQR 19–34). 770 HCV positive prediabetic patients were enrolled, 398 untreated controls and 372 DAAs treated patients. Overall, the CV events annual incidence was much higher among prediabetic treated patients (1.77 vs. 0.62, p &lt; 0.001), and HCV clearance demonstrated to significantly reduce CV events (RR: 0.411, 95%CI 0.148–1.143; p &lt; 0.001), with an estimated NNT for one additional patient to benefit of 52.1. Moreover, an independent association between a lower rate of CV events and HCV clearance after DAAs was observed (OR 4.67; 95%CI 0.44–53.95; p = 0.016). HCV eradication by DAAs allows a significant reduction of MACEs in the prediabetic population, and therefore represents a primary objective, regardless of the severity of liver disease and CV risk factors. •Even in prediabetes HCV infection coexistence exacerbates cardiovascular risk.•HCV clearance demonstrated to significantly reduce CV events.•HCV clearance by DAAs was independently associated with a lower rate of CV events.•The use of DAAs in HCV positive prediabetic patients would be recommended.</description><subject>Cardiovascular risk</subject><subject>Direct acting antivirals</subject><subject>Hepatitis C virus</subject><subject>Prediabetes</subject><issn>0939-4753</issn><issn>1590-3729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9UDtPwzAYtBBIlMI_YPBYhgQ7tptmQarKo5UqsQCr5ccX6qqJg50U8e9xFWaW73G6O-kOoVtKckro_H6ft0MDxuYFKWhOeJ7AMzShoiIZK4vqHE1IxaqMl4JdoqsY94SwkjA-QXrTdMr02NfYugDpSp9rP7Fqe3d0QR0inj0ul_EO-xYbFazzRxXNcFABwxHaPmLX4vXqAxu_86HH367f4S5AZp3S0EO8Rhd1soGbvz1F789Pb6t1tn192ayW28wwVvWZWSyErq3minBbGspqEOUCtBWlKYTmRUqiSibmXIFWWguthKiVAEIKC0yxKZqNvl3wXwPEXjYuGjgcVAt-iLIQTNAiTZqofKSa4GMMUMsuuEaFH0mJPFUq93KsVJ4qlYTLBCbZwyiDFOPoIMhoHLQGxuqk9e5_g197mIJE</recordid><startdate>20210722</startdate><enddate>20210722</enddate><creator>Sasso, Ferdinando Carlo</creator><creator>Pafundi, Pia Clara</creator><creator>Caturano, Alfredo</creator><creator>Galiero, Raffaele</creator><creator>Vetrano, Erica</creator><creator>Nevola, Riccardo</creator><creator>Petta, Salvatore</creator><creator>Fracanzani, Anna Ludovica</creator><creator>Coppola, Carmine</creator><creator>Di Marco, Vito</creator><creator>Solano, Antonio</creator><creator>Lombardi, Rosa</creator><creator>Giordano, Mauro</creator><creator>Craxi, Antonio</creator><creator>Perrella, Alessandro</creator><creator>Sardu, Celestino</creator><creator>Marfella, Raffaele</creator><creator>Salvatore, Teresa</creator><creator>Adinolfi, Luigi Elio</creator><creator>Rinaldi, Luca</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7761-7533</orcidid><orcidid>https://orcid.org/0000-0003-3320-3878</orcidid><orcidid>https://orcid.org/0000-0002-9142-7848</orcidid><orcidid>https://orcid.org/0000-0001-6958-927X</orcidid></search><sort><creationdate>20210722</creationdate><title>Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes</title><author>Sasso, Ferdinando Carlo ; Pafundi, Pia Clara ; Caturano, Alfredo ; Galiero, Raffaele ; Vetrano, Erica ; Nevola, Riccardo ; Petta, Salvatore ; Fracanzani, Anna Ludovica ; Coppola, Carmine ; Di Marco, Vito ; Solano, Antonio ; Lombardi, Rosa ; Giordano, Mauro ; Craxi, Antonio ; Perrella, Alessandro ; Sardu, Celestino ; Marfella, Raffaele ; Salvatore, Teresa ; Adinolfi, Luigi Elio ; Rinaldi, Luca</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-c885bfdb4a04d7c13fe578ebd57c25b42372a73564aebabb5ba55fa5e002de3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cardiovascular risk</topic><topic>Direct acting antivirals</topic><topic>Hepatitis C virus</topic><topic>Prediabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sasso, Ferdinando Carlo</creatorcontrib><creatorcontrib>Pafundi, Pia Clara</creatorcontrib><creatorcontrib>Caturano, Alfredo</creatorcontrib><creatorcontrib>Galiero, Raffaele</creatorcontrib><creatorcontrib>Vetrano, Erica</creatorcontrib><creatorcontrib>Nevola, Riccardo</creatorcontrib><creatorcontrib>Petta, Salvatore</creatorcontrib><creatorcontrib>Fracanzani, Anna Ludovica</creatorcontrib><creatorcontrib>Coppola, Carmine</creatorcontrib><creatorcontrib>Di Marco, Vito</creatorcontrib><creatorcontrib>Solano, Antonio</creatorcontrib><creatorcontrib>Lombardi, Rosa</creatorcontrib><creatorcontrib>Giordano, Mauro</creatorcontrib><creatorcontrib>Craxi, Antonio</creatorcontrib><creatorcontrib>Perrella, Alessandro</creatorcontrib><creatorcontrib>Sardu, Celestino</creatorcontrib><creatorcontrib>Marfella, Raffaele</creatorcontrib><creatorcontrib>Salvatore, Teresa</creatorcontrib><creatorcontrib>Adinolfi, Luigi Elio</creatorcontrib><creatorcontrib>Rinaldi, Luca</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nutrition, metabolism, and cardiovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sasso, Ferdinando Carlo</au><au>Pafundi, Pia Clara</au><au>Caturano, Alfredo</au><au>Galiero, Raffaele</au><au>Vetrano, Erica</au><au>Nevola, Riccardo</au><au>Petta, Salvatore</au><au>Fracanzani, Anna Ludovica</au><au>Coppola, Carmine</au><au>Di Marco, Vito</au><au>Solano, Antonio</au><au>Lombardi, Rosa</au><au>Giordano, Mauro</au><au>Craxi, Antonio</au><au>Perrella, Alessandro</au><au>Sardu, Celestino</au><au>Marfella, Raffaele</au><au>Salvatore, Teresa</au><au>Adinolfi, Luigi Elio</au><au>Rinaldi, Luca</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes</atitle><jtitle>Nutrition, metabolism, and cardiovascular diseases</jtitle><date>2021-07-22</date><risdate>2021</risdate><volume>31</volume><issue>8</issue><spage>2345</spage><epage>2353</epage><pages>2345-2353</pages><issn>0939-4753</issn><eissn>1590-3729</eissn><abstract>Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort. In this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We recorded all CV events occurred during an overall median follow-up of 24 months (IQR 19–34). 770 HCV positive prediabetic patients were enrolled, 398 untreated controls and 372 DAAs treated patients. Overall, the CV events annual incidence was much higher among prediabetic treated patients (1.77 vs. 0.62, p &lt; 0.001), and HCV clearance demonstrated to significantly reduce CV events (RR: 0.411, 95%CI 0.148–1.143; p &lt; 0.001), with an estimated NNT for one additional patient to benefit of 52.1. Moreover, an independent association between a lower rate of CV events and HCV clearance after DAAs was observed (OR 4.67; 95%CI 0.44–53.95; p = 0.016). HCV eradication by DAAs allows a significant reduction of MACEs in the prediabetic population, and therefore represents a primary objective, regardless of the severity of liver disease and CV risk factors. •Even in prediabetes HCV infection coexistence exacerbates cardiovascular risk.•HCV clearance demonstrated to significantly reduce CV events.•HCV clearance by DAAs was independently associated with a lower rate of CV events.•The use of DAAs in HCV positive prediabetic patients would be recommended.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.numecd.2021.04.016</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7761-7533</orcidid><orcidid>https://orcid.org/0000-0003-3320-3878</orcidid><orcidid>https://orcid.org/0000-0002-9142-7848</orcidid><orcidid>https://orcid.org/0000-0001-6958-927X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0939-4753
ispartof Nutrition, metabolism, and cardiovascular diseases, 2021-07, Vol.31 (8), p.2345-2353
issn 0939-4753
1590-3729
language eng
recordid cdi_proquest_miscellaneous_2535122531
source ScienceDirect Freedom Collection
subjects Cardiovascular risk
Direct acting antivirals
Hepatitis C virus
Prediabetes
title Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A44%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20direct%20acting%20antivirals%20(DAAs)%20on%20cardiovascular%20events%20in%20HCV%20cohort%20with%20pre-diabetes&rft.jtitle=Nutrition,%20metabolism,%20and%20cardiovascular%20diseases&rft.au=Sasso,%20Ferdinando%20Carlo&rft.date=2021-07-22&rft.volume=31&rft.issue=8&rft.spage=2345&rft.epage=2353&rft.pages=2345-2353&rft.issn=0939-4753&rft.eissn=1590-3729&rft_id=info:doi/10.1016/j.numecd.2021.04.016&rft_dat=%3Cproquest_cross%3E2535122531%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c339t-c885bfdb4a04d7c13fe578ebd57c25b42372a73564aebabb5ba55fa5e002de3a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2535122531&rft_id=info:pmid/&rfr_iscdi=true